product name Adefovir Dipivoxil
Description: Adefovir Dipivoxil is a reverse transcriptase inhibitor, used in the treatment of chronic hepatitis B virus (HBV). It is an antiviral acyclic nucleoside phosphonate (ANP) analog and a dipivoxil formulation of adefovir, a nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV). Adefovir Dipivoxil is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) that works by blocking reverse transcriptase for the treatment of hepatitis B. Adefovir dipivoxil is not effective against HIV-1.
References: Antiviral Res. 2002 Jul;55(1):27-40.
501.47
Formula
C20H32N5O8P
CAS No.
142340-99-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (199.4 mM)
Water: <1 mg/mL
Ethanol: 100 mg/mL (199.4 mM)
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Adefovir Dipivoxil reduces Liver HBV DNA to <0.1 pg of viral DNA per mg of total DNA (pg/mg) in transgenic mice expressing hepatitis B virus. Adefovir Dipivoxil treatment also reduces serum HBV DNA to 3.5 log10 genomic equivalents (ge)/mL in transgenic mice expressing hepatitis B virus compared to 5.3 log10 ge/mL for the placebo control group. Adefovir Dipivoxil antiviral activity reaches near maximum viral reduction by day 10 in the liver and reaches an endpoint of liver virus inhibition at 1.0 mg/kg/day. |
| Animal model | |
| Formulation & Dosage | |
| References | Antiviral Res. 2002 Jul;55(1):27-40. |
